MedCity News January 18, 2022
ProKidney is going public in a SPAC merger that infuses the biotech with $825 million for Phase 3 tests and manufacturing of its autologous cell therapy for chronic kidney disease. More than slowing the decline in organ function, ProKidney says its cell therapy offers the potential to reverse injury caused by the condition.
Currently available chronic kidney disease therapies can slow the condition’s progression, but they can’t stop the decline in organ function. Regenerative medicine company ProKidney is offering the potential for a different outcome—tissue repair. The biotech is conducting a pivotal test of its cell therapy, and it has agreed to a merger deal that takes the company public and infuses it with $825 million to support its clinical...
Today's Sponsors
Today's Sponsor